



ADVANSOURCE BIOMATERIALS TO ATTEND MEDTEC EUROPE 2010 EXHIBITION

COMPANY TO PROMOTE EUROPEAN COUNCIL DECISION 1999/534/EC COMPLIANT PRODUCTS

Wilmington, MA. March 19, 2010... AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced it will be exhibiting at the MEDTEC Europe 2010 Exhibition and Conference being held at the Landesmesse Stuttgart Messepiazza in Stuttgart, Germany, from March 23-25, 2010. The Company will continue promoting its expanding line of innovative biomaterials focused on the product development needs of the medical device community.

Khristine Carroll, AdvanSource's Senior Vice President of Commercial Operations, stated, "MEDTEC Europe is a key venue for informing international medical device companies about AdvanSource Biomaterials' value added services and rapidly expanding line of polymer technologies. Given our recent verification and declaration of material compliance with European Council Decision 1999/534/EC, as it applies to protection against transmissible spongiform encephalopathies, we are very encouraged by the potential partnerships available within the European community and will be focusing on this important material advantage. We are looking forward to the opportunity to showcase this feature, in addition to our newest innovations, to both current and targeted partner companies at this show. The European marketplace is a significant target within our commercial efforts as we execute on our business plan; and we are pleased with the response we have received towards this end from the European device community. We encourage medical device professionals and the investment community to sign-up for the Exhibit at www.devicelink.com/expo/medtec10/index_en.html and meet with us at this event."

Representatives of the Company's senior management and sales staff will be in attendance at booth 554.

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about AdvanSource is available at its website: www.advbiomaterials.com.

Forward-Looking Statements

AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and are subject to risks and



uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2009, September 30, 2009, and December 31, 2009. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact:

AdvanSource Biomaterials Corporation

Khristine Carroll, Sr. VP of Commercial Operations

978-657-0075, ext 134

kcarroll@advbiomaterials.com

David Volpe, Acting CFO

(978) 657-0075, ext. 103

dvolpe@advbiomaterials.com